Semaxanib

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameSemaxanib
Drug Alias Namesemaxanibum司马尼布司马沙尼Semoxindsemaxanib +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVascular endothelial growth factor receptor 2 antagonists
TargetsVascular endothelial growth factor receptor 2
Therapy Area/IndicationsSkin MelanomaCNS Embryonal TumorSolid tumours +[30] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSugen LlcPfizer IncThe University Of Chicago +[5] 
Active IndicationsN/A
Inactive IndicationsSkin MelanomaCNS Embryonal TumorSolid tumours +[30] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG